Bellicum Therapy Reduces Risk from Mismatched Stem Cell Transplants – TheStreet.com
TheStreet.com |
Bellicum Therapy Reduces Risk from Mismatched Stem Cell Transplants
TheStreet.com Bellicum is developing the additive T cell therapy, known as BPX-501, to boost the efficacy and safety of certain types of potentially curative stem cell transplants. Today, these transplants, sourced from donors who are not a perfect match, are used … Bellicum Pharmaceuticals Announces BPX-501 Clinical Data Demonstrating Disease … |
